Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model
Anirban Roy, … , Mingfu Wu, Ashok Kumar
Anirban Roy, … , Mingfu Wu, Ashok Kumar
Published April 18, 2023
Citation Information: JCI Insight. 2023;8(10):e164768. https://doi.org/10.1172/jci.insight.164768.
View: Text | PDF
Research Article Muscle biology Therapeutics

Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model

  • Text
  • PDF
Abstract

Muscular dystrophies make up a group of genetic neuromuscular disorders that involve severe muscle wasting. TGF-β–activated kinase 1 (TAK1) is an important signaling protein that regulates cell survival, growth, and inflammation. TAK1 has been recently found to promote myofiber growth in the skeletal muscle of adult mice. However, the role of TAK1 in muscle diseases remains poorly understood. In the present study, we have investigated how TAK1 affects the progression of dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). TAK1 is highly activated in the dystrophic muscle of mdx mice during the peak necrotic phase. While targeted inducible inactivation of TAK1 inhibits myofiber injury in young mdx mice, it results in reduced muscle mass and contractile function. TAK1 inactivation also causes loss of muscle mass in adult mdx mice. By contrast, forced activation of TAK1 through overexpression of TAK1 and TAB1 induces myofiber growth without having any deleterious effect on muscle histopathology. Collectively, our results suggest that TAK1 is a positive regulator of skeletal muscle mass and that targeted regulation of TAK1 can suppress myonecrosis and ameliorate disease progression in DMD.

Authors

Anirban Roy, Tatiana E. Koike, Aniket S. Joshi, Meiricris Tomaz da Silva, Kavya Mathukumalli, Mingfu Wu, Ashok Kumar

×

Figure 2

Inactivation of TAK1 in young mdx mice blunts growth and reduces muscle force production.

Options: View larger image (or click on image) Download as PowerPoint
Inactivation of TAK1 in young mdx mice blunts growth and reduces muscle ...
(A) Schematic representation showing age of mdx mice, time of TAK1 inactivation, and euthanasia. (B) Average body weight of littermate mdx;Tak1fl/fl and mdx;Tak1mKO mice at indicated ages. (C) Gross appearance of mdx;Tak1fl/fl and mdx;Tak1mKO mice at the age of 8 weeks. (D) Percentage increase in body weight of mdx;Tak1fl/fl and mdx;Tak1mKO mice with age. (E) Average 4-paw grip strength per gram of body weight of 8-week-old mdx;Tak1fl/fl and mdx;Tak1mKO mice. n = 4–6. (F–H) Quantification of normalized (F) average specific twitch force, (G) tetanic forces to stimulation frequency relationship, and (H) peak tetanic force over 180 seconds in 8-week-old mdx;Tak1fl/fl and mdx;Tak1mKO mice. n = 7–9. (I–K) Wet weight of (I) GA and (J) TA muscle and (K) fold change in serum levels of CK activity in mdx;Tak1fl/fl and mdx;Tak1mKO mice at 5 and 8 weeks of age. n = 3–6. Data represented as mean ± SEM. *P ≤ 0.05, values significantly different from corresponding mdx;Tak1fl/fl mice by unpaired Student t test (B, D, E, F, I, J, and K) or by 1-way ANOVA (G and H) followed by Tukey’s multiple-comparison test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts